We used the same categorization as in the Western New York Breast Cancer Study (WNYBCS) [5], the most comprehensive study assessing CYP17 genotype as a potential effect modifier, in an attempt to replicate findings with an independent data set. This evidence concerns the gene CYP17A1 and breast cancer.